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Effect of single doses of inhaled lignocaine on F 
and bronchial reactivity in asthma 
T. W. HARRISON AND A. E. TATTERSFIELD 
Division of Respiratory Medicine, Nottingham City Hospital, UK 
Inhaled lignocaine appeared to have considerable steroid sparing properties in an uncontrolled trial in 20 patients 
with oral-steroid-dependent asthma. Since it can also cause bronchoconstriction, safety needs to be studied under 
controlled conditions. We have performed a randomized, double-blind, placebo-controlled study in 20 patients with 
mild to moderate asthma to determine the effects of single doses of inhaled lignocaine 40 and 160 mg compared to 
saline. Saline and lignocaine 40 and 160 mg caused an initial fall in FEV,, mean maximum change being 0.13, 0.19 
and 0.23 1 respectively with no significant difference between treatments (P=O.2). There was no fall in FEV, 
following salbutamol pretreatment and lignocaine had no significant effect on heart rate or blood pressure or on 
bronchial reactivity to methacholine carried out at 90 min after inhalation. These results show that single doses of 
inhaled lignocaine are well tolerated in subjects with mild to moderate asthma and that any tendency to 
bronchoconstriction can be prevented with salbutamol pretreatment. 
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Introduction 
Severe asthma is difficult to treat and many patients require 
long-term treatment with oral corticosteroids, sometimes in 
high doses. Corticosteroids have serious adverse effects but 
alternative therapies such as azathioprine, methotrexate 
and cyclosporin have limited ability to reduce maintenance 
oral corticosteroids and have significant adverse effects of 
their own (1). In an uncontrolled 2-year study in 20 
patients, inhaled lignocaine (between 40 and 160 mg four 
times a day) allowed 13 of the subjects to stop oral 
corticosteroids completely (2). In this study only one sub- 
ject reported chest tightness after lignocaine inhalation. 
These findings need to be confirmed in a controlled 
study, but before doing this more information is needed 
about the safety of nebulised lignocaine in subjects with 
asthma. In contrast to the study by Hunt et al., four 
single-dose studies have demonstrated bronchoconstriction 
following lignocaine inhalation (3-6). We have performed 
a double-blind, placebo-controlled study to determine the 
time-course of the effect of inhaled lignocaine on forced 
expiratory volume in 1 s (FEV,), blood pressure and heart 
rate and its effect on bronchial reactivity to methacholine in 
20 subjects with mild to moderate asthma. We also looked at 
the effect of pretreatment with salbutamol to see whether this 
would prevent any bronchoconstriction. Lignocaine plasma 
levels were measured at 30 and 60 min post-inhalation. 
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Methods 
SUBJECTS 
Twenty subjects aged 24-62 years with stable asthma and 
no other relevant illness were studied. Inclusion criteria 
were: subjects had to be current non-smokers, have an 
FEV, greater than 50% predicted, an increase in FEV, of 
at least 15% in response to 200,ug inhaled salbutamol and 
a provocative dose of methacholine causing a fall in FEV, 
of 20% (PDZO) of 12pmol or less. Apart from taking 
short-acting beta-agonists as required, 13 subjects were 
taking up to 800 pg per day of an inhaled corticosteroid and 
two were taking a long-acting beta-agonist. Subjects gave 
written consent to the study which was approved by the 
Nottingham City Hospital ethics committee. 
MEASUREMENTS 
FEV, was measured with a dry bellows spirometer 
(Vitalograph; Buckingham, U.K.) as the higher of two 
readings within 100 ml. The PD,, methacholine was 
measured by a modification of the method of Yan et al. (7). 
Subjects inhaled three puffs of saline from a DeVilbiss 
nebuliser (DeVilbiss Health Care Inc, Pennsylvania, 
U.S.A.) whilst breathing in slowly from functional residual 
capacity to total lung capacity, followed by doubling 
doses of methacholine from 0.048 to 12pmol. FEV, was 
measured 1 min after each dose and the test stopped when 
it had fallen by 20% from the post-saline value. PD,, was 
calculated by linear interpolation of the last two readings 
on the log dose-response plot. Blood pressure and heart 
rate were recorded by an automated sphygmomanometer 
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(Lifestat 200, Physio-Contro Corporation, Washington, 
U.S.A.) and plasma lignocaine levels assayed by fluor- 
escence polarization immunoassay, using the TDx/TDxFLx 
lignocaine assay (Abbott Laboratories, U.S.A.). 
PROTOCOL 
The study had a randomized, placebo-controlled, double- 
blind design. Subjects taking an inhaled steroid kept the 
dose constant throughout the study whilst short-acting 
beta-agonists and long-acting beta-agonists were withheld 
for at least 6 and 14 h respectively before each visit. 
Subjects attended the laboratory for two screening visits to 
ensure they fulfilled the inclusion criteria and had a normal 
physical examination and electrocardiogram. Subjects ful- 
filling the entry criteria then attended at the same time on 
5 study days. 
On each study day a cannula (Butterflya, Abbot Ireland, 
Sligo, Republic of Ireland) was inserted into a forearm 
vein followed by a 15-min rest before baseline measure- 
ments of FEV,, heart rate and blood pressure were per- 
formed. Subjects then inhaled saline or salbutamol 2.5 mg 
followed 15 min later by saline or lignocaine hydrochloride 
40 or 160 mg (Xylocaine 4% Topical Solution, Astra 
Pharmaceuticals Ltd, Kings Langley, U.K.) diluted to 4 ml 
with normal saline. The treatment option of salbutamol 
followed by saline was not included to reduce the number 
of visits. All treatments were inhaled via a Pari LC nebuliser 
with filter and valve set and driven by a Pari Master 
compressor unit (mass median diameter 3.1 pm, total out- 
put 0.5 g min - i. Pari, Starnberg, Germany). In an attempt 
to disguise the ;aste and oral anaesthesia associated with 
inhaled lignocaine, one spray of 4% lignocaine was applied 
to the subject’s tongue whilst they exhaled, immediately 
before the second nebulisation. FEV,, blood pressure and 
heart rate were recorded before and at 5, 10, 15, 30, 45, 60, 
and 90 min after the second nebulisation and methacholine 
PD,, was determined at 90 min providing FEV, was within 
10% of baseline. A venous blood sample was withdrawn at 
30 and 60 min, separated and stored at - 20°C for subse- 
quent assay of plasma lignocaine concentration. The assays 
were confined to samples following the 160 mg dose of 
lignocaine, identified after the study code had been broken. 
Subjects took nothing by mouth for 1 h post-inhalation. 
Twenty subjects were studied to provide at least 95% 
power to detect one standard deviation (SD) difference in 
FEV, between lignocaine and saline at a significance level 
of 0.05. 
ANALYSIS 
The effect of the initial inhalation of salbutamol or saline 
on FEV, is expressed as mean change from baseline with 
95% confidence intervals (CI). The effects of the second 
inhalation of lignocaine or saline on FEV,, blood pressure 
and heart rate are expressed as the mean change from 
the measurements taken immediately prior to the second 
nebulisation. PD,, values for methacholine were log- 
transformed for analysis and differences in PD,, measured 
in doubling doses. Area under the curve was determined for 
heart rate and blood pressure and expressed as an average 
over the 90 min. Treatment effect was determined by 
two-way ANOVA with a P-value of 0.05 considered as 
statistically significant. Mean values are given with 95% CI. 
Results 
Twenty subjects (eight female) were entered, although one 
withdrew after the first day for personal reasons and is 
excluded from the analysis. Demographical details of the 
subjects are presented in Table 1. The mean screening FEV, 
was 2.6 1 (77% predicted) and baseline FEV, values did not 
differ significantly on the 5 study days. 
All patients reported a bitter taste and oropharyngeal 
numbness following the lignocaine spray to the tongue and 
nebulised lignocaine and this persisted for approximately 
30 min. Subjects were unable to differentiate between 
inhaled saline and lignocaine 40 mg, whereas most found 
that lignocaine 160 mg was more unpleasant and produced 
a change in voice character. 
INITIAL INHALATION 
At 15 min following the initial nebulisation mean FEV, had 
fallen by 0.04 (95% CI: 0.003-0.08) 1 (1.5%) from baseline 
after saline and had increased by 0.42 (95% CI: 0.35-0.5) 1 
(16%) following salbutamol (Fig. 1). 
SUBSEQUENT INHALATION 
Following inhaled saline 
Inhalation of saline and lignocaine 40 and 160 mg caused a 
transient fall in mean FEV, (Fig. 2). The maximum indi- 
vidual fall in FEV, was 0.4, 0.5 and 0.87 1 (16, 16 and 26% 
of baseline) and the mean maximum fall in FEV, was 0.13, 
0.19 and 0.23 1 (5, 7 and 9% of baseline) following saline, 
lignocaine 40 and 160 mg respectively (ANOVA: P=O.2). 
The difference between saline and lignocaine 160 mg 
was 0.1 1 (95% CI: - 0.03-0.23 1). FEV, had returned to 
baseline by 30 and 45 min after inhalation of saline and 
lignocaine, respectively. There was no relation between 
maximum change in FEV, following lignocaine and 
baseline FEV, or methacholine PD,,. 
Bronchial reactivity to methacholine was measured in the 
19 subjects on all three occasions. Methacholine PD,, did 
not differ significantly following inhalation of lignocaine 
and saline, the differences from saline PD,, being 0.05 (95% 
CI: - 0.440.54) and - 0.18 ( - 0.46-0.1) doubling doses 
following lidocaine 40 and 160 mg, respectively. 
Neither dose of inhaled lignocaine had any significant 
effect on systolic blood pressure or heart rate (both P>O.3) 
although there was a small increase in mean diastolic blood 
pressure of 3.8 mmHg (95% CI: - 0.02-7.46) following 
lignocaine 160 mg compared with saline, but this was not 
significant (P=O,O9). 
Following pretreatment with salbutamol 
There was no fall in FEV, following inhalation of lignocaine 
40 or 160 mg after pretreatment with salbutamol (Fig. 1). 
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TABLE 1. Details of age, sex: spirometry, methacholine PD,, and usual treatment for the 20 patients 
studied 
Patient FEV, FEV, Methacholine 
no. Age Sex (1) (% predicted) PD,, Cum011 Treatment 
1* 43 M 3.0 78 1.54 
2 62 M 2.1 62 0.145 
3 20 M 3.75 84 5.1 
4 48 F 2.6 100 0.58 
5 59 F 1.3 57 0.59 
6 46 F 2.35 84 6.12 
I 42 M 2.3 65 1.15 
8 56 F 1.35 63 1.1 
9 44 F 2.6 82 1.3 
10 24 M 4.5 100 2.35 
11 38 F 2.3 80 0.17 
12 38 M 3.3 79 0.64 
13 46 M 2.25 59 1.3 
14 51 F 2.4 94 1.2 
15 46 M 3.6 78 6.7 
16 43 M 2.8 70 1.4 
17 53 M 2.5 72 3.06 
18 33 M 3.45 70 5.2 
19 40 M 2.5 68 0.77 
20 62 F 1.7 85 2.7 
Mean (SD) 44 2.6 (0.8) 76.5 (12.6) 1,4** (2.9) 
Salb, FP 250pg 
Salb, Sm; BDP 800,~g 
Tb 
Salb, Sm, BDP 500,~g 
Salb, BDP 400 ,ug 
Salb, BDP 400,~g 
Salb 
Salb, BDP 200,~g 
Salb, BDP 400,~g 
Salb 
Salb 
Salb, BDP 400,~g 
Salb 
Salb; BDP 200,~g 
Salb 
Salb; BDP 400,~g 
Salb, BDP 800,~g 
Salb 
Salb; BDP 400,~g 
Salb, Bud 2OOpg 
BDP= beclomethasone dipropionate; Bud = budesonide; FP= fluticasone propionate (dose as daily 
dose); Salb= salbutamol as required; Tb = terbutaline as required; Sm= salmeterol. 
“Subject withdrawn. ““Geometric mean. 
s 0.3 
i 
E 
,/’ Saline or lignocaine 
d 
0.0 
-0.31 ’ I y I I I 
-15 0 20 40 60 80 100 
Time (min) 
FIG. 1, Change in FEV, (1) following initial inhalation of salbutamol (- - -) and sa!ine (-) and following subsequent 
inhalation of saline (0); lignocaine 40 mg (H) and lignocaine 160 mg (A). 
Plasma lignocaine levels were 0.35 (s~=@l4) and 0.28 
(0.08)pg ml- ’ at 30 and 60 min respectively after 160 mg 
lignocaine. Levels were unaffected by pretreatment with 
salbutamol. 
Discussion 
If lignocaine is found to be an effective treatment for 
asthma it could be a useful alternative to oral prednisolone. 
Before embarking on more extensive studies in patients 
with severe asthma we wished to determine the safety of 
inhaled lignocaine in patients with less severe asthma 
because previous studies have reported considerable bron- 
choconstriction. We found that inhaled lignocaine 40 and 
160 mg caused a small mean fall in FEV, of 7 and 9%, 
respectively, but its effect did not differ significantly from 
the 5% fall that occurred after normal saline. One subject 
had a large (26% of baseline) fall in FEV, following 
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FIG. 2. Maximum change in FEV, following saline and 
lignocaine 40 and 160 mg in individual subjects. 
inhalation of lignocaine 160 mg and this was prevented by 
pretreatment with salbutamol. We found no change in 
bronchial reactivity to methacholine at 90 min when the 
local anaesthetic effects of lignocaine had worn off. 
Lignocaine is difficult to study because it has a bitter taste 
which is easily recognized and because oral anaesthesia may 
affect the ability to carry out spirometry. We attempted to 
blind the treatment options with a spray of banana- 
flavoured 4% lignocaine applied to the subject’s tongue 
immediately prior to lignocaine, and saline inhalation. 
Although it was only effective in masking the lower dose of 
lignocaine it caused an unpleasant taste and oral anaes- 
thesia on all 5 days so that any effect of a noxious stimulus 
or oral anaesthesia on the patient’s ability to perform spiro- 
metry would be similar on all 5 days. Application of the 
lignocaine spray during expiration should not have affected 
the airways and up to 10 sprays of 2% lignocaine to the 
throat had no effect on FEV, in asthmatic subjects in a 
previous study (8). 
Four of the five (3-6,9) previous single-dose studies in the 
literature have reported bronchoconstriction following 
inhaled lignocaine but interpretation is difficult for the 
reasons outlined above and because two of the studies were 
not controlled (5,6). Patients may bronchoconstrict to 
inhaled normal saline, as in our study, so we cannot be sure 
that the response in the uncontrolled studies was due to 
inhaled lignocaine. In the three studies comparing ligno- 
Caine and saline, two showed a larger fall in FEV, or 
maximal mid-expiratory flow following lignocaine com- 
pared with saline (3,4) whilst the other did not (9). Only one 
previous study included subjects taking inhaled steroids (6). 
Taken together these studies suggest that lignocaine can 
cause bronchoconstriction in some patients with asthma, 
although the mean fall is less than previously reported. Our 
study suggests that pretreatment with 2.5 mg salbutamol 
should protect against any bronchoconstriction but the 
effects of a smaller dose given by an inhaler are unknown. 
Since beta-agonists were not withheld during the study by 
Hunt et al. (2) this may explain why only one subject 
reported chest tightness with no fall in FEV,. 
Studies carried out within 30 min of inhaled lignocaine or 
during a lignocaine infusion have shown a small reduction 
in bronchial responsiveness to methacholine (4), histamine 
(10) and acetylcholine (11) but not cold air (12). At these 
times lignocaine would still have local anaesthetic activity 
which could inhibit reflex-mediated bronchoconstriction. 
We performed the methacholine challenge after 90 min so 
that FEV, would have returned to baseline and any effect of 
local anaesthesia on the ability to carry out spirometry 
would be reduced. Furthermore if lignocaine has beneficial 
effects in asthma they will probably need to extend beyond 
the duration of local anaesthesia. 
In agreement with other studies we found no significant 
change in heart rate or systolic blood pressure following 
inhalation of lignocaine (9,13). The small increase in dia- 
stolic blood pressure of 3.8 mmHg following lignocaine 
160 mg was not significant although it is consistent with i.v. 
studies in humans and dogs (14). 
Thus, in our study, patients with mild to moderate 
asthma did not bronchoconstrict significantly more to 
lignocaine than to normal saline. When a bronchoconstric- 
tor effect was seen it was inhibited by pretreatment with 
salbutamol. It is possible that patients with more severe 
asthma may have more marked bronchoconstriction and 
we are now studying the safety and efficacy of inhaled 
lignocaine in oral-steroid-dependent patients. 
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